Peter Wardell
Peter is a Director with EY-Parthenon leading the London office for the EMEIA Life Sciences Strategy Team. He focusses primarily on corporate, commercial, and operations strategy for pharmaceutical and med-tech companies. His expertise includes growth strategy, commercial execution strategy, manufacturing, and supply chain network optimization and digital solution implementation. He has a strong understanding of small molecules, biologics, biosimilars as well as cell and gene technologies. Peter has also helped execute large transactions, including functional carve-out execution for global pharmaceutical companies. Before joining EY, he worked as a strategy consultant at PwC Strategy& and was a Director and Board Member for a Japanese pharmaceutical supplier of complex manufacturing systems.
Peter has an MBA from the University of Chicago with a concentration in Analytic Finance and an Honours Bachelor of Science from McMaster University in Canada.